Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on LinkedIn:
“A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.”
Title: A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group
Authors: Maha Hameed, Alma Habib, Abdullah Mohammad Khan, Mehak Masood Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyuong Ryu Tiger, Mansi Shah, Hira Shaikh, Christopher Strouse, Kimberly Green, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend
Read The Full Article
Other articles about Multiple Myeloma on OncoDaily.